Floatz logo

Nbt-Nm108

Multiple Sclerosis

Suhayl Dhib-Jalbut, MDPhase 1/2Active
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
65/ 100

Competitive context

182 Active assets in the Multiple Sclerosis cohort.

Asset / SponsorPhaseRating
Ocrevus
Polpharma Biologics International AG
Phase 4BBB
Fampridine
MGH Institute of Health Professions
Phase 4BBB
Cladribine
University Hospital, Strasbourg, France
Phase 4BBB
Nabiximols
Jazz Pharmaceuticals
Phase 4BBB
Teriflunomide
Sanofi
Phase 4BBB

View all 50 →

Same molecule, other indications

Nbt-Nm108 is also rated in:

Prader-Willi syndromeDormant
B
Indicative ·
57 / 100
View asset →
colon carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
malignant colon neoplasmDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →